View Cart
Global Information, Inc.
US:
+1-860-674-8796
EU:
+32-2-535-7543
SG:
+65-6223-2436
Home
|
Category
|
Publishers
|
Custom Research
|
E-mail Alert
|
About Us
|
Contact Us
|
Site Map
|
Pharmaceutical
Drug Discovery
Drug Delivery System
Veterinary Medicine
Bone Disease Treatment
Obesity Treatment
Generic Drugs
OTC Drug
Prescription Drugs
Vaccines
Regulation
Cancer
Diabetes
Infection Disease
Mental Disease
Pharmaceutical Companies
Neurodegenerative Disease
View All Categories
Home
>
Category
>
Pharmaceutical
>
Market Research Report
Guide to Good Clinical Practice, 3rd Edition
Published by
Drug & Market Development Publications
Published
2007/09
Content info
468 pages
Product code
DM56526
Price
From
US $ 995
US $ 995
PDF by E-mail (Single User License)
How to Order?
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Table of Contents
Chapter 1: Executive Summary
Chapter 2: Introduction
The Phases of Clinical Study
Clinical Trials Design and Analysis
Corporate Implications of Non-compliance with GCP
Chapter 3: International Regulations Governing GCP
History of GCP Legislation
Current Regulations
U.S.A
Canada
Japan
Chapter 4: The Elements of GCP Compliance
Introduction
The Principles of ICH GCP
Standard Operating Procedures as Tools for GCP Compliance
Chapter 5: The Sponsor?Duties and Responsibilities
General Responsibilities of the Sponsor
Contract Research Organization (CRO)?312.52
Medical Expertise
Trial Design and Management
Investigator Selection and Assignment of Duties and Functions
Compensation and Financing
Submissions to Regulatory Authorities
Investigator' s Brochure (IB)
Investigational Drug Products
Record Access
Safety Information and Adverse Drug Effects Reporting
Annual Reports
Study Monitoring
Non-compliance
Premature Trial Termination or Suspension
Trial Reports
Regional Variations of Sponsor' s GCP Responsibilities
Chapter 6: The Clinical Investigator?Duties and Responsibilities
Qualifications and Agreements
Communication with IRB
Investigational Drug Products
Informed Consent
Records and Reports
Progress Reports
Safety Reports
Final Investigator' s Report
Common Technical Document Requirements
Premature Trial Termination or Suspension
Regional Variations of Investigator' s GCP Responsibilities
Chapter 7: The Institutional Review Board/Independent Ethics Committee (IRB/IEC)
Responsibilities
Composition and Operations
Review Procedures
Subject Recruitment Advertising
Informed Consent Form
DHHS Regulations
Records
Regional Variations of IRB Duties and Responsibilities
Chapter 8: The Investigator' s Brochure
General Considerations
Brochure Contents
Chapter 9: The Clinical Trial Protocol
General Information
Background Information
Study Purpose and Objectives
Study Design
Selection, Withdrawal, and Treatment of Subjects
Assessments of Efficacy and Safety
Statistical Analyses
Other Provisions
Data Handling and Record Keeping?Computerized Systems
Protocol Amendments
Chapter 10: Essential Documents for Trial Conduct
Introduction
Before the Trial
During the Clinical Phase
After Completion or Termination
Chapter 11: Internal and External Monitoring and Inspections
Sponsor' s Monitoring
Selection and Qualification of Monitors
Extent and Nature of Monitoring
Monitor' s Responsibilities
Pre-investigation Visits
Visits During the Study
Study Follow-up Visits
Monitoring Reports
Sponsor' s Study Audit
Purpose
Selection and Qualification of Auditors
Auditing Procedures
Regulatory Inspections
Sponsor and Monitor Inspections
IRB Inspections
Investigator/site Inspections
How to Cope with Audits and Inspections
Before the Event
During the Inspection
After the Event
Regulatory follow-up Action and Sanctions
Chapter 12: Checklists and Forms for Monitoring and Audits
Chapter 13: References and Further Reading
Access to Regulatory Documents
Guidelines to GCP
Advisory Bodies, Publications and Web Sites
Clinical Trial Management Companies and Consultants
Chapter 14: Text of Regulations and Guidelines
U.S.A. Code of Federal Regulations, Title 21
Guidance for Industry Computerized Systems Used in Clinical Investigations
Canada
Japan
New European Directives
ICH Consolidated Guideline
The Declaration of Helsinki
TABLE OF EXHIBITS
Exhibit 2.1 Stages of Drug Development
Exhibit 2.2 Drug Clinical Trial Phases
Exhibit 2.3 Classification of Clinical Studies by Objectives
Exhibit 3.1 Member Nations of the European Union
Exhibit 3.2 Comparison of GCP Regulations and ICH Guidelines
Exhibit 3.3 Consolidated Guideline, as Adopted by the Three ICH Regions
Exhibit 4.1 The Clinical Trial Triangle
Exhibit 4.2 SOP Form for a Laboratory Test
Exhibit 4.3 SOP Form for a Procedure
Exhibit 4.4 Minimum List of SOPs for a Clinical Study
Exhibit 6.1 Diagram of the CTD
Exhibit 6.2 Contents of CTD Clinical Summary Sections in Module 2
Exhibit 6.3 Content of CTD Efficacy Section, Module 5
Exhibit 8.1 Contents of an Investigator' s Brochure
Exhibit 10.1 Essential Documents Required Before the Trial Starts
Exhibit 10.2 Documents Generated During the Trial
Exhibit 10.3 Documents to be Added After the Trial
Exhibit 12.1 IRB Checklist
Exhibit 12.2 Monitoring Visit Report
Exhibit 12.3 CRF Review Form
Exhibit 12.4 Source Data Verification Form
Exhibit 12.5 Clinical Site Regulatory Binder Check List
Related Report
Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate
Emerging Markets Series: Indonesia and Philippines
Booming Clinical Trials Market in India
The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry
The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
Please inform me when related publications are released
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.